NCNbio srl

E' alle sue battute conclusive il "Forum nazionale sulla medicina di precisione" di Palermo organizzato da Fondazione Heal (ente che riconosce fra i suoi fondatori l'Università degli studi di Palermo) sotto l'egida del Ministero Istruzione, Universita' e Ricerca. Il CEO di NCNbio srl MariaLuisa Nolli è presente in qualità di membro dello Steering Committee Progetto Heal Italia coordinato da Massimo Dominici. Come ha sottolineato il Rettore massimo midiri, l'evento ha rappresentato un ulteriore passo avanti nell’ambizioso percorso intrapreso da Heal Italia "per stimolare un dibattito di alto profilo, al livello nazionale ma anche europeo ed extraeuropeo, sul cambio epocale che la Sanità può intraprendere grazie alla ricerca nel campo della medicina personalizzata e di precisione". Il Forum è stata una straordinaria occasione di confronto con i rappresentanti delle istituzioni e i principali protagonisti dei settori scientifici e tecnologici coinvolti in questa trasformazione destinata a rendere il network della ricerca traslazionale italiana sempre più competitivo e ad introdurre la medicina di precisione nel sistema sanitario nazionale. European Commission Italia Domani Regione Siciliana Giorgio Stassi #medicinapersonalizzata #medicinadiprecisione #ricercatraslazionale

There are plenty of packaging needs in the biopharma field, each of them requires specific competencies in order to be met. CIT Pharma is the partner of choice for a wide range of contract packaging activities, even the most challenging ones, in every market and for all pharmaceutical forms.   Based on our 39-year history, leading commercial companies as well as important CMOs have already chosen us as preferred partners.   Interested in discovering all the packaging opportunities for your product? 🖊️ e-mail to: federico.casaglia@citpharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   Welcome to CIT Pharma, where packaging innovation takes shape #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma

The CEO of NCNbio srl MariaLuisa Nolli will be the moderator of the roundtable discussion of Mind your STEM, a one-of-a-kind event where science, innovation, tech trends, and hands-on experiences come together to shape the future. The roundtable discussion will be held by: Craig Glastonbury - Research Group Leader Human Technopole | Marco Cappelletti - GM MED & Central Europe Illumina | Francesco Maria Senatore - BD Director Bio4Dreams | Matteo Moretti - Research Group Leader IRCCS Ospedale Galeazzi Sant'Ambrogio Gruppo San Donato | Chiara Brioschi - Sr Researcher Early Stage Innovation Bracco. Mind your STEM is open to all University students from scientific faculties and will take place on 4 February 2025 from 9.30 to 13.00 at Human Technopole. ➡️ For more information: https://lnkd.in/dtCsB4hT ➡️ Register here: https://lnkd.in/dZAqGdj7 Marta Nathansohn

Perché avvalersi di una #consulenza specializzata sulle #terapieavanzate? 🧬 Poter contare sulla disponibilità di professionisti dedicati ti lascia la possibilità di dedicare più risorse agli aspetti di business 🧬 Il supporto di #competenze specifiche riduce il rischio di errori connessi agli adempimenti regolatori 🧬 Risparmi tempo, elemento determinante per viaggiare di pari passo con un'innovazione rapidissima. Scegli un partner solido e affidabile in grado di seguirti lungo tutta la filiera del #technologytransfer. Scegli NCNbio. #consulenzabiotech #consulenzaterapieavanzate #atmp

Riprendiamo a parlare di espansione del #manufacturing e di #decentralizzazione della produzione che sarà sicuramente uno degli strumenti più utili ed efficienti nella produzione di dosi per i pazienti non solo di #CART ma di molte altre #ATMP Preme però chiarire che la decentralizzazione con point of care dedicati di manufacturing deve essere di prodotti che seguono l’iter appropriato dello sviluppo del farmaco e non, se non in casi di emergenza clinica, prodotti che seguono #hospitalexemption(HE). In Italia #HE è regolato e questo garantisce che la qualità delle ATMP che arrivano al paziente sia eccellente e i prodotti sicuri

Making Europe's Biorevolution Happen 🌱When we combine biology with technology with the aim of accelerating the Green Transition, we enter the world of Biosolutions.   💶The companies involved in this journey face many regulatory and economic barriers in their efforts to bring new and more sustainable bio-based products and solutions to the market: to compete, Europe needs to scale up.   💡In this case collection, the European Biosolutions Coalition shares examples of what the European biosolutions sector has to offer the world. We are proud to announce that Biosphere S.r.l is among the selected companies. 👏Thank you European Biosolutions Coalition and Assobiotec for the involvement of Biosphere S.r.l in this initiative and thanks to all the team of Danish Industry and FRIDAY agency for their contribution. Take a look at how we bring sustainability to an industrial scale: get to know us and the amazing biosolutions we represent.   You find Biosphere S.r.l at pag. 18! #biotechnology #greenchemistry #biocatalysis #fermentation #bioeconomy #sustainability #CDMO #enzymes

📢 I’m thrilled to share some exciting news! Our company has officially joined European Biosolutions Coalition, an important milestone for us in Biosphere S.r.l. It’s an honor to be part of such a collaborative and innovative environment, and I’m looking forward to contributing to the success of this partnership alongside my amazing colleague Giulia Maltoni and the rest of the team. #Teamwork #Innovation #NewBeginnings

Presenting the frontrunners of the biorevolution: Biosphere S.r.l🌱   Innovative biosolutions and the companies who produce them can make Europe's biorevolution happen. And today we zoom in on one of those companies – BioSphere💡   Biosphere is a key player in the Italian industrial biotechnology sector and works as a technology platform, delivering deep tech along with research-based scaling facilities in which other companies can improve and test their products🔬   Biosphere is also known for its development of tailor-made enzymes and microorganisms for a variety of market sectors. For example, Biosphere develops optimised microbial strains that can improve a plant’s nutrient uptake and protect against diseases🌾The company is also involved with the creation of cosmetic💄, nutraceutical and food ingredients that have enhanced properties thanks to the fermentation processes🍴   Turning today’s chemical industry into a biobased one requires strong collaboration between scientists and industry. Biosphere is a key facilitator in this collaboration, helping new and innovative biosolutions to go from idea to reality🚀   But high-quality research calls for high funding. First and foremost, there is a big need for funding in high-quality research, ensuring high level training for graduates in several different fields. Funding is also crucial in supporting the development of existing scale-up facilities, to appropriately cover the gap between ideas and industrial applications💶   Let’s accelerate the biorevolution with a bold Biotech Act!🌱 You can find our case catalogue here: https://lnkd.in/dH6GtTET

NCNbio is pleased to announce the participation of the CEO MariaLuisa Nolli as keynote speaker at "The Biotech Revolution: Advanced Therapies from Concept to Cure", organised by The Healthcare and Life Sciences Club - POLIMI Graduate School of Management. The event will take place on March 5, 2025 | 6.30 PM at POLIMI Graduate School of Management | Campus Navigli | Milan 🔗 Register now to secure your spot: https://lnkd.in/dGpv3R4c Silvia Ceragioli Michela Cristofolini Silvia Barbera Fortuna Elena Lo Baido Elena Sambugaro Matteo Bruno, EMBA Gabriele Saccardo Giorgio Di Dato Natascia Colantoni Giorgia Di Massimo Veronica Cusumano Tirado Federico Frattini Antonella Moretto Emanuele Lettieri Paolo Locatelli #atmp #terapieavanzate #consulenzabiotech #consulenzaterapieavanzate

On 12 January 2025 the new regulation on health technology assessment (HTAR) (Regulation (EU) 2021/2282), an important step forward in accelerating and widening access to new medicines, has become applicable. The new rules will initially apply to new active substances to treat cancer and to all advanced therapy medicinal products (ATMPs). As the Executive Director Emer Cooke has stated: “EMA welcomes the new HTA regulation and is ready to do what it takes to support the European Commission and the Member States in its successful implementation”. *** Il 12 gennaio 2025 è entrato in vigore il nuovo regolamento Health Technology Assessment (HTAR) (Regulation (EU) 2021/2282), un passo importante verso l’accelerazione e l’ampliamento dell’accesso alle nuove cure. La normativa sarà in una prima fase applicata ai nuovi attivi finalizzati al trattamento dei tumori e a tutti i medicinali per terapie avanzate (ATMPs). Come dichiarato dal Direttore Esecutivo Emer Cooke: “EMA dà il benvenuto al nuovo regolamento HTA ed è pronta a fare tutto ciò che serve per supportare la Commissione Europea e gli Stati membri nella sua implementazione“. European Medicines Agency #hta #regolamentohta #consulenzaterapieavanzate #consulenzabiotech #atmp #rerapieavanzate https://lnkd.in/eAznQ347